Approaches for Systemic Delivery of Dystrophin Antisense Peptide Nucleic Acid in the mdx Mouse Model
June 4, 2021
June 4, 2021
Videoconference and publication of the results for the 2020-2021 financial year, on June 16, 2021
June 1, 2021
June 1, 2021
Poly(ethylene glycol)-b-poly(1,3-trimethylene carbonate) Copolymers for the Formulation of In Situ Forming Depot Long-Acting Injectables
April 22, 2021
April 22, 2021
Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin
April 19, 2021
April 19, 2021
MedinCell: mdc-CWM clinical phase 3 will start in 2021
March 25, 2021
March 25, 2021
Poly(ethylene glycol)-b-poly(1,3-trimethylene carbonate) Amphiphilic Copolymers for Long-Acting Injectables: Synthesis, Non-Acylating Performance and In Vivo Degradation
March 6, 2021
March 6, 2021
Covid-19: MedinCell publishes an extensive Ivermectin Safety Expert Analysis
March 5, 2021
March 5, 2021
Expert Review Report: Medical Safety of Ivermectin
March 3, 2021
March 3, 2021
Tremendous success for MedinCell’s €30 million capital increase for qualified investors
February 11, 2021
February 11, 2021
MedinCell announces a capital increase of a c.€30 million
February 10, 2021
February 10, 2021
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
